Enovis (NYSE:ENOV - Get Free Report) had its price objective reduced by investment analysts at Needham & Company LLC from $64.00 to $57.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Needham & Company LLC's price target indicates a potential upside of 57.07% from the company's previous close.
Enovis Price Performance
NYSE ENOV traded down $1.06 on Friday, hitting $36.29. 628,932 shares of the company's stock were exchanged, compared to its average volume of 1,027,427. The stock has a 50-day moving average of $35.18 and a 200-day moving average of $41.55. Enovis has a 52 week low of $29.32 and a 52 week high of $53.84. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -16.57 and a beta of 1.79.
Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. The business had revenue of $558.83 million during the quarter, compared to the consensus estimate of $558.80 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Enovis's quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.50 earnings per share. Analysts expect that Enovis will post 2.79 earnings per share for the current year.
Institutional Trading of Enovis
Large investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. grew its stake in Enovis by 0.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 6,207,768 shares of the company's stock valued at $237,199,000 after acquiring an additional 44,632 shares in the last quarter. Humankind Investments LLC lifted its position in Enovis by 8.6% in the first quarter. Humankind Investments LLC now owns 5,688 shares of the company's stock valued at $217,000 after purchasing an additional 452 shares during the last quarter. Quantbot Technologies LP bought a new stake in Enovis in the 1st quarter worth $1,973,000. Dimensional Fund Advisors LP raised its position in Enovis by 1.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,927,340 shares of the company's stock valued at $111,852,000 after purchasing an additional 27,894 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in Enovis in the first quarter worth $1,069,000. 98.45% of the stock is owned by hedge funds and other institutional investors.
Enovis Company Profile
(
Get Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Featured Stories
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
